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I.  INTRODUCTION 
1.  Objective of  the  report 
The  Commission  has  recently  presented  Its  proposals  for  the  future 
system  for  the  free  movement  of  medicinal  products  (both  for  human  and 
veterinary  use)  within  the  Communlty<1>,  Including  a  substantial 
exp 1  ana tory  memorandum  whIch  provIdes  the  background  to  the  I  ntro-
ductlon of  the  proposals.  The  objectives of  the  future  system  can  best 
be  met  by  a  nuanced  approach  Involving  two  authorization  procedures; 
one  decentrallsed  and  the  other  centralized.  These  procedures  have 
been  elaborated  from  the  experience  gained  with  the  current  Community 
procedures,  namely  the  'multi-state'  and  'concertatlon'  procedures. 
This  report  Is  an  opportunity  to  present  the experience and  results of 
the  current  procedures  In  respect of  medicinal  products  for  human  use, 
against  which  the  proposals  for  the  future  system  may  be  considered. 
This  document  also  reports,  In  accordance  with  the  first  paragraph  of 
Article  15  of  Council  Directive  75/319/EEc<2>,  on  the  operation  of 
the  procedure  laid  down  In  chapter  111  of  that  Directive  (  I.e.  multi-
state procedure)  and  Its effects on  the  development  of  Intra-Community 
trade,  thus updating earl ler  reports<3>. 
(1)  COM(90)283  of  14.11.1990 
(2)  In  order  to facilitate  reading of  this  report,  texts of  the  CommunHy 
pharmaceutical  legislation cited are  summarized  In  chronological  order 
In  Annex  1. 
(3)  Reports  from  the  Commission  to  the  Council  on  the  operation  of  the 
Committee  for  Proprietary Medicinal  Products: 
COM(79)  59  of  22.2 .1979; 
COM(80)  149  of  31 .3.1980; 
COM(81)  363  of  13.7.1981 ; 
COM(82)  787  of  3.12.1982; 
COM(84)  437  of  3 .12.1984,  (explanatory memorandum); 
COM(88)  143  of  22 .3.1988. - 3  -
The  first  Community  procedure  for  the  co-ordination  of  national 
actions  on  appl lcatlons  for  marketing  authorizations,  which  had  been 
established  by  Directive 75/319/EEC,  was  extensively  documented  In  the 
1988  report  to  the  Councl I  cited  above.  This  earlier  procedure  ceased 
to  function  once  the  new  'multi-state'  procedure  came  Into  operation 
towards  the  end  of  1986.  However,  given  certain  simi larltles  between 
It  and  the  multi-state,  It  Is  Illustrative  to  compare  the  experience 
gained with  each  procedure. 
Directive  87/22/EEC  Introduced  on  1st  July  1987  a  further  Community 
procedure,  namely  the  'concertatlon'  procedure.  This  Community 
procedure  differs  fundamentally  from  the  multi-state  procedure  In 
that,  It  Is  appl lcable  prior  to  any  national  decisions  concerning  high 
techno I  ogy  medIc I  nes,  part I  cuI a r I  y  those  p reduced  by  b I  a techno I  ogy. 
Although  only  In  place  for  a  few  years,  some  Illustration  of  Its 
operation  can  already  be  given. 
2.  Content  of  the  report 
The  present  report  of  the  Commission  to  the  Council  relates  to  the 
global  activities of  the  Committee  for  Proprietary  Medicinal  Products 
and  Its  working  parties,  and  Includes  the  operation  of  the  two 
Community  procedures  (multi-state  and  concertatlon)  for  the  co-ordi-
nation  of  national  authorizations  to  place  medicines  for  human  use  on 
the  market,  In  accordance  with  Community  legislation,  as  well  as 
developments  In  the  area  of  pharmacovlgl lance  and  International 
harmonisation. - 4  -
In  performing  Its  role  as  set  out  In  Directive  75/319/EEC,  the 
Committee  for  Proprietary  Medicinal  Products  (CPMP)  ,gives  an  opinion 
as  to  whether  a  particular  medicinal  product  compiles  with  .,the  re-
quirements  set  out  In  Directive  65/65/EEC.  Its  activities  are 
therefore  not  restricted  to  new  applications  for  marketing  authori-
zations,  but  also  Include  appropriate  scientific  and  administrative 
requirements  for  the  making  of  appl !cations  for  marketing  authorizat-
Ions.  Much  of  this  work  Is  accomplished  by  the  CPMP  through  Its 
w9rklng  parties and  expert  groups,  which  provide  an  Invaluable support 
to  the  Committee  and  to  the  Commission. 
The  work  of  the  CPMP  does  not  end  with  the decision  to grant  or  refuse 
a  marketing  authorization.  The  Committee  maintains  a  watchful  eye  on 
the  medicinal  products  on  the  market  and  Is  constantly  active  In 
monitoring  the safety  and  efficacy of medicines  on  the market,  and  any 
change  to  the  side effect  profile of  a  medicinal  product.  This  latter 
activity,  known  as  pharmacovlgl lance,  has  progressively  expanded  and 
a  number  of  Innovative  procedures  have  been  adopted. 
On  the  basis  of  Its  expertise,  the  CPMP  has  also  supported  the 
Commission  In  International  discussions  on  technical  requirements  for 
the  authorization  of  medicinal  products,  the  exchange  of  scientific 
knowledge  and  efforts  towards  International  harmonisation  of  testing 
requirements  for  pharmaceutical  products. 
In  order  to  reflect  the  wide  scope  of  activity  of  the  Committee,  all 
of  these  aspects  are considered. - 5  -
I I.  ACTIVITIES  OF  THE  CPMP 
1.  Membership  of  the Committee 
1.1  The  Committee  for  Proprietary  Medicinal  Products,  In  accordance  with 
Its  Rules  of  Procedure  (111/492/77),  consists  of  one  representative 
for  each  Member  State  and  one  representative  of  the  Commission.  One 
alternate  Is  appointed  for  each  of  the  representatives.  A  I 1st  of  the 
current  membership  of  the  CPMP  Is  given  In  Annex  2. 
1.2  The  Committee  elects  Its  chairman  from  among  Its  members  by  absolute 
majority  and  secret  ballot.  The  term  of  office  of  the  chairman  shall 
be  three  years,  renewable  once  only.  Until  September  1988, 
Dr.  Teljgeler,  had  served  two  successive  terms.  Professor 
D.  Pogglollnl  was  then  elected  and  currently serves  as  chairman. 
1.3  Two  deputy  chairmen  are  appointed,  one  elected  by  the  Committee  and 
the  other  appointed  by  the  Commission.  In  May  1989,  Professor 
J.M.  Alexandre  was  elected  deputy  chairman,  while  Mr.  Fernand  Sauer 
continues  to serve as  deputy  chairman  representing  the  Commission. - 6  -
2.  Communication  and  Information 
2.1  The  work  of  the  CPMP  Is  of  pivotal  Importance  In  the  appllcatl.on  of 
the  Community  pharmaceutical  directives.  Equally  the  views  of  the  CPMP 
on  a  range  of  Issues are of  considerable  Interest  and  relevance  to  the 
pharmaceutical  Industry.  Given  the  volume  of  Information  produced,  the 
services  of  the  Commission  have  brought  together  the  rel.evant  texts 
and  published  them  In  a  series  entitled  'Rules  governing  Medicinal 
Products  In  the  European  Communlty•(4).  This  series  was  first 
publ !shed  In  January  1989,  and  In  keeping  with  the  Committee's  policy 
of  openness,  wl  I I  be  updated  and  expanded  progressively. 
*Volume  I  of  the  series  contains  the  binding  texts  adopted  by  the 
Community  relating  to  medicinal  products  for  human  use.  Catalogue 
number  CB-55-89-706-EN-C. 
*Volume  II  Is  the  Notice  to  Applicants,  which  replaced  the  version 
publ lshed  In  1986.  Catalogue  number  CB-55-89-293-EN-C. 
*Volume  Ill  contains  technical  guidelines  dealing  with  qual lty  In-
c I  ud I  ng  b I  otechno I  ogy  testIng,  pharmaco-tox I  co I  og I  ca I  and  c I In I  ca I 
studies.  Catalogue  number  CB-55-89-843-EN-C. 
*Volume  IV  Is  the guldel lne  on  Good  Manufacturing  Practice.  Catalogue 
number  CB-55-89-722-EN-C. 
There  Is  also  a  Volume  v to  the  series  which  deals  exclusively  with 
veterinary medicinal  products. 
(4)  uRules  governing  medicinal  products  In  the  European  Community", 
available  from  the  Office  for  Official  Publications  of  the
1 European 
Communities,  2  rue  Mercier,  L-2985  Luxembourg - 7  -
3.  Standard  appl lcatlon dossier 
3.1  At  a  very early stage,  the  CPMP  Identified  the  need  to ensure a  common 
base  of  Information  as  a  prerequisite  for  harmonlsed  decisions  on 
applications  for  marketing  authorization,  which  also  allowed  simpli-
fication  and  transparency  of  the  appl lcatlon  process.  Thus  In  1986,  a 
document  known  as  the  "Notice  to  Appl lcants"  was  produced.  Since  then 
this  text  has  been  extensively  revised and  expanded.  This  revised  text 
was  publ lshed  In  January  1989  and  contains detailed  Information on  the 
compilation  of  the  appl lcatlon  dossier,  as  well  as  the  preparation of 
expert  reports,  the  Importance  and  value of which  Is  high I lghted. 
3.2  The  preparation  of  the  Notice  to  Applicants  was  done  by  an  ad  hoc 
group  of  national  experts  specialised  In  regulatory  affairs.  During 
the  course  of  prepar lng  the  document,  a  number  of  Important  points 
which  reQuired  consideration  became  evident.  Therefore,  the  group  was 
formal lsed on  24.5.89  and  became  known  as  the Operations working  party 
of  the  CPMP.  Dr.  Teljgeler  (former  chairman  of  the  CPMP  from  1983  -
1988)  was  appointed  chairman  of  this working  party. 
This working  party  Is  concerned  with  the  procedural  and  administrative 
requirements  of  appl lcatlons  for  marketing  authorizations,  as  wei  I  as 
other  regu I  a tory  Issues.  Thus  the  group  Is  preparIng  a  harmon I  sed 
administrative section  (Part  lA)  of  the  appl lcatlon dossier  for  use  In 
any  Member  State,  as  wei  I  as  harmonlsed  positions  on  general 
administrative aspects. 
This  working  party  will  be  active  In  preparing  the  third  "Notice  to 
Applicants"  In  parallel  with  the  considerations  of  the  Commission's 
proposals  by  Council  and  Parliament,  which  are  planned  for  1991; 
however  the  current  text  of  Notice  to  Appl lcants will  remain  In  force 
until  1992. - 8  -
4.  Harmonisation of scientific requirements 
4.1  Council  Directive  75/318/EEC,  as  amended,  sets  out  the  laws  relating 
to  analytical,  pharmaco-toxlcologlcal  and  clinical  standards  and 
protocols  In  respect  of  the  testing  of  medicinal  products.  Since  Its 
establishment,  the  CPMP  has  attached  a  high  priority  to  the  preparat-
Ion  of  guidelines  on  the  quality,  safety  and  efficacy  of  medicinal 
products. 
4.2  These  guldel lnes  serve  a  two-fold objective.  Firstly,  they  are  Inten-
ded  to  provide  a  basis  for  a  practical  harmonisation  of  the  manner  In 
which  the  Member  States  Interpret  and  apply  the  detal led  requirements 
for  the  demonstration of  quality,  safety and  efficacy contained  In  the 
Community  directives.  Secondly,  they  are  Intended  to  facilitate  the 
preparation  of  appl lcatlons  for  marketing  authorization  which  are 
recognised  as valid by  all  12  Member  states. 
4. 3  The  Ru I  es  governIng  MedIc Ina I  Products  In  the  European  Commun l ty, 
volume  1 I I  (see 2.1  above)  contains guidelines  publ lshed  up  to January 
1989.  A list of  guldel lnes  adopted  and  prepared since  then  Is  given  In 
Annex  3  and  w  I I I  be  pub I I  shed  as  an  addendum  to  Vo I  ume  I I I  of  the 
series  'Rules governing  Medicinal  Products  In  the  European  Community'. 
5.  Working  parties 
5.1  At  an  early  stage  In  Its operation,  the  CPMP  Identified  the  need  for 
specialist  support  In  a  range  of  scientific areas.  Therefore  a  number 
of  working  parties  were  set  up  (Efficacy  and  Safety  In  1977,  Quality 
In  1985,  Pharmacovlgllance  and  Operations  In  1989).  These  working 
parties  which  are  Intrinsically  part  of  the  CPMP,  support  the 
Committee  In  Its  role  of  giving  scientific  opinions  on  applications 
received  through  the Community  procedures. - 9  -
5.2  In  parallel  In  1985,  the  Commission  set  up  a  working  party on  biotech-
nology,  with  the  Joint  tasks  of  helping  the  Commission  In  the  pre-
paration  and  technical  requirements  for  the  'biotechnology'  Directive 
(see  Annex  1),  and  a  second  function  which  Is  of  growing  relevance, 
the  preparation  of  discussions  for  CPMP  opinions  on  applications  for 
products  derived  from  biotechnology. 
5.3  With  the  growing  numbers  and  Indeed  complexity  of  appl lcatlons,  the 
working  party  structures  have  adapted  by  operating  In  a  flexible, 
responsive  and  selective  manner.  This  Involves  the  working  parties 
working  Jointly  on  Identified  problems;  Individual  experts  being 
convened  In  ad  hoc  expert  meetings;  or  Invited  specialists  Joining  a 
working  party  for  a  specific  discussion.  A  recent  example  was  the 
special  expert  meeting  on  AIDS  products  held on  6.6.90. 
5.4  The  facl I lty  of  convening  disparate  experts,  from  diverse  disciplines 
has  become  an  Integral  part  of  the  operat Jon  of  the  CPMP  and  Its 
working  parties,  given  the  necessity  to  merge  and  blend  expertise  so 
as  to  obtain  an  overall  assessment  of  benefit/risk.  The  success  of 
this  flexible  structure,  which  wit 1  be  further  developed,  means  that 
the  CPMP  wl  It  be  wei  I  placed  to  deal  with  the  wide  array  of  applicat-
Ions  and  act  as  a  bridge  from  today's  activities  Into  the  future 
system. 
5.5  This  flexlbl llty  of  the  working  party  structure  also  permits  a  large 
number  of  European  experts  to  feed  Into  the  system.  Current Jy  there 
are  several  hundreds  of  experts  aval table  for  a  CPMP  opinion,  and  the 
lists  of  available  experts  nationally  are  continuously  updated.  The 
principle areas of scientific activity divide as  follows: - 10 -
*Efficacy:  Guided  by  Its chairman,  Prof.  J.M.  Alexandre,  the Efficacy 
working  party  has  considered  both  general  Issues  and  topics  of 
specific  therapeutic  concern.  A most  Important  guideline  which  was 
finalized  In  July  '90  was  "Good  Clinical  Practice  (111/3976/89)". 
Over  the  period  1988  to October  '90,  the  working  party  met  8  times, 
with  4  drafting  group  meetings.  Special  experts  were  co-opted  for 
guidelines  on  Anti-cancer  medicinal  products  (from  EORTC),  Radio-
pharmaceuticals and  Bloavallabll lty. 
*Operations:  As  described  above  (paragraph  3.2 of  this Chapter),  this 
working  party  Is  chaired  by  Dr.  C.  Teljgeler. 
*  Pharmacovlgl lance:  With  Prof.  Royer  as  chairman,  this  recently 
establ lshed  working  party  Is  preparing  harmonlsed  approaches  for  the 
monitoring  and  collection  of  Information  on  adverse  drug  reactions 
(ADR's).  In  addition  to  11  meetings,  the  working  party  has  liaised 
with  the  World  Health  Organisation  on  the  International  monitoring 
scheme. 
*Quality:  With  the  stewardship of  Its  chairman,  Mr.  A.C.  Cartwright, 
the  qual lty  working  party  has  been  confronted  with  and  has  success-
fully  resolved  an  Important  number  of  difficult  problems.  The 
working  party  has  collaborated  with  the  Efficacy,  Safety  and 
Biotechnology  working  parties  In  turn  on  a  range  of  guidelines  and 
Identified  problems.  In  the  last  two  years  there  have  been  11  full 
meetings of  the  working  party,  two  drafting groups  I.e.  Radlopharma-
ceutlcals  (Dr.  K.  Kristensen)  and  Herbal  Remedies  (Prof.  Hefendehl); 
and  5  ad  hoc  groups. 
*Safety:  Under  the  chairmanship of  Prof.  R.  Bass,  the  safety  working 
party  has  considered  a  diverse  range  of  topics.  In  parallel  with  Its 
work  on  guldel lnes,  the  group  has  also  considered  the  toxicology  of 
a  selection  of  substances.  The  working  party  met  on  7  occasions, 
consulted  outside  experts  on  lmmmunotoxlclty  and  reproduction 
toxicity  and  convened  3  drafting groups  for  selected  topics. - 11  -
5.6  Moreover,  with effect  from  1st  July  1987,  the Councl I  has  delegated  to 
the  Commission  the  power  to  amend  the  Annex  to  Directive  75/318/EEC 
which  contains  the  legal  requirements  for  the  conduct  of  analytical 
and  pharmaco-toxlcologlcal  tests  and  cl lnlcal  trials.  With  the  adopt-
Ion  of  the  'Extension'  Directives  setting  out  additional  provisions 
for  Immunological  medicinal  products  consisting of  vaccines,  toxins or 
serums  and  allergens;  radlopharmaceutlcals;  medicinal  products  derived 
from  human  blood  or  human  plasma,  It  Is  necessary  to modify  the  tech-
nical  Annex  to  Directive  75/318/EEC  relating  to analytical,  pharmaco-
toxlcologlcal  and  clinical  standards  and  protocols  In  respect  of  the 
testing of  medicinal  products. 
The  CPMP  and  Its  working  part les  have  assisted  the  Commission  In 
preparing  appropriate  revisions,  In  order  to  take  account  of 
scientific  progress.  9  ad  hoc  drafting  groups  on  Immunological 
products,  vaccines  In  general  and  Influenza  vaccine  In  particular, 
comprising  experts  from  diverse  dlsclpl lnes,  have  considered  the 
appropriate  revisions,  which  will  be  considered  by  the  Committee  on 
the Adaptation  to  technical  progress of  the Directives  In  1991. - 12  -
II I.  MULTI-STATE  PROCEDURE 
1.  Principles of  the multi-state procedure 
1.1  The  legal  rules  governing  the  multi-state  procedure  are  set  out  In 
Chapter  Ill  of  Directive  75/319/EEC,  as  amended  by  Directive 
83/570/EEC.  A full  explanation  of  the  multi-state  procedure  Is  given 
In  the  Notice  to Appl lcants. 
1.2  The  primary  purpose  of  the multi-state  procedure  Is  to make  It  easter 
for  a  person  who  has  already obtained a  marketing  authorization  In  one 
Member  State  to  get  further  marketing  authorizations  for  the  product 
concerned  In  two  or  more  of  the other  Member  States.  The  reduction of 
the  number  of  Member  States  concerned  from  five  to  two  was  one  of  the 
changes  Introduced  In  the  new  procedure  {effective 1.10.86). 
1 . 3  The  bas Is  upon  whIch  the  mu It 1-sta  te  procedure  was  estab I I  shed  was 
that  a  medIc Ina I  product,  manufactured  and  marketed  1  n  one  Member 
State  on  the  basis  of  harmonized  provisions,  should  be  allowed  Into 
another  Member  State,  taking  Into  due  consideration  the  Initial 
authorization,  save  In  exceptional  cases  which  would  be  submitted  to 
the  Committee  for  Proprietary  Medicinal  Products.  On  this  account, 
only exceptional  cases would  be  referred  to  the  CPMP  for  opinion. 
1.4  On  the  basis  of  the  same  documentation,  and  taking  the  marketing 
authorization  granted  by  the  first  Member  State  In  due  consideration, 
the  authorities  of  the  Member  States  to  which·  an  appl lcatlon  Is 
addressed  have  120  days  to  grant  authorization  to  market  the  product 
In  their  country or  to formulate  reasoned objections. - 13-
1. 5  Where  one  or  more  object Ions  are  advanced,  the  matter  Is  referred  to 
the  CPMP  which  considers  the  grounds  for  the  objections  and  any 
written or  oral  explanations  provided  by  the  appl !cant,  before  Issuing 
I t s  op I  n I  on . 
1.6  This opinion,  which  Is  not  legally binding,  Is  addressed  to  the Member 
States  and  to  the  applicant.  Within  a  period  of  60  days  from  the  date 
of  the  opinion,  the  Member  States  must  decide  on  what  action  to  take 
pursuant  to  the  CPMP  opinion  and  must  Inform  the  CPMP  of  their 
decision. 
2.  Operation of  the multi-state procedure 
2.1  In  order  to examine  the  operation of  the  multi-state  procedure,  It  Is 
useful  to  Identify  the  key  steps  that  punctuate  the  procedure  (figures 
for  each  step are  up  to  the  end  of  October  1990). 
1st  step:  the  applicant  company  notifies  Its  Intention  to  start  a 
multi-state  procedure .......  142  appl !cations  (of  which  3 
applications  were  withdrawn  as  the  appl lcant  did  not  comply 
with  the  reQuirements  of  Article  9  of  Directive  83/570/EEC, 
whl  le  2  further  applications were  withdrawn  due  to detection 
of  serious side-effects). 
2nd  step:  the  concerned  Member  States  confirm  the  receipt  of  a  val ld 
application  and  the  period  of  120  days  In  Article  9  of 
Directive  75/319/EEC  Is  Initiated  by  a  telex  from  the 
Commission  to  the  Member  States ...  122  appl !cations - 14  -
3rd step:  a  Member  State  takes  due  consideration  of  the  first 
authorization  and  authorises  the  medicinal  product  ....  no 
application  I.e.  0%  of  applications 
OR 
raises  reasoned  objections  within  the  120  day  period  laid 
down  by  the  Directive ......  122  applications  I.e.  100%  of 
appllcat Ions 
4th step:  the  CPMP  gives  an  opinion  on  applications  referred  to  It 
..... 92  applications 
5th  step:  all  concerned  Member  States  notify  the  action  they  have 
taken on  the basis of  the opinion ...... completed  procedures 
I.e.  for  which  all  concerned  Member  States  have  notified 
their  decision,  45  applications. 
2.2  Up  to  the  end  of  1990,  the multi-state procedure  has  proven  to be  much 
more  popular  than  the  previous  procedure  at  142  appl lcatlons  In  four 
years  vs.  41  appl lcatlons  In  eight  years. 
The  following  chart  Illustrates  the  number  of  multi-state  procedures 
which  have  started  each  year  (I.e.  based  on  the  start  of  the  120  day 
period),  broken  down  by  Quarter: 
1986  1987  1988  1989 
Q2  Q3  Q4  Q1  Q2  Q3  Q4  Q1  Q2  Q3  Q4  Q1  Q2  Q3  Q4 
1  1  1  8  6  7  6  5  6  8  11  7  10  13  9 
1990 
Q1  Q2  Q3 
7  7  6 - 15  -
2.3  These  142  procedures  correspond  to  a  total  of  738  national  applicat-
Ions.  Thus  the  average  multi-state  procedure  concerns  a  little  more 
than  five  (  5.20}  recipient  countries.  This  Is  Interesting  as  one  of 
the  Improvements  requested  and  Indeed  Implemented  with  the 
Introduction  of  the  new  multi-state  procedure  (Directive  83/570/EEC} 
was  to  reduce  the  threshold  for  entry  to  the  procedure  from  a  minimum 
of  5  countries  to  2  countries.  It  might  be  suggested  therefore  that 
the  benefit  In  reducing  numbers  was  psychological  rather  than  actual I 
Of  these  142  applications  52%  were  for  more  than  5  Member  States. 
whl 1st  only  18%  were  for  2  Member  States.  T~e breakdown  Is  as  follows: 
Coverage  (numbers)  of  countries  by  appl lcatlons 
No.  of countries concerned: 
No.  of  appl lcatlons  : 
2  3  4  5  6  7  8  9 
25  26  16  12  15  11  16  12 
10 
9 
2.4  The  task  of  originally  authorizing  Member  State  In  the  multi-state 
procedure  has  fallen  most  heavily  on  two  Member  States  I.e.  United 
Kingdom  and  France.  The  preference  for  these  original  Member  States 
was  also evidenced  In  the  previous  procedure. 
Whilst  alI  Member  States  are  concerned  In  the  multi-state  procedure. 
Germany  Is  by  far  the  most  frequent  recipient.  This  may  be  due  to  the 
delays  which  currently exist  with  appl lcatlons  In  Germany. - 16  -
Former  CPMP  procedure  (Directive  75/319/EEC)  1978-1986 
BE  OK  DE  GR  ES  FR  IR  IT  LX  NL  UK  Total 
Country  of  origin  5  7  5  7  1  16  41 
Recipient  country  33  26  25  12  15  24  28  37  35  18  253 
Multi-state procedure  (Directive 83/570/EEC)  1986-0ctober  '90 
BE  OK  DE  GR  ES  FR  IR  IT  LX  NL  UK  Total 
Country of  origin  7  13  11  34  14  9  11  43  142 
Recipient  country  78  54  102  66  70  49  49  79  74  68  49  738 
2.5  In  accordance  with  the  terms  of  the  Act  of  Accession,  Portugal  Is  not 
required  to  Implement  Council  Directives  65/65/EEC,  75/318/EEC, 
75/319/EEC,  78/25/EEC,  83/570/EEC,  until  1  January  1991. 
However  the  Portuguese  authorities  have  Indicated  that  they  wl  11 
accept  national  applications presented  In  accordance with  the standard 
Community  format  (I.e.  Notice  to Applicants). 
3.  Outcome  of  the  procedure 
3.1  The  actual  experience  of  the  multi-state  procedure  Is  not  consistent 
with  the  spirit  of  the  directive  which  Introduced  It,  since  every 
single  multi-state  application  has  been  referred  for  a  CPMP  opinion, 
even  though  the  safeguard  clause  was  only  Intended  to  be  used  In 
exceptional  cases. - 17  -
3.2  The  degree  to  which  Member  States  tak:e  Into  due  consideration  the 
first  authorization  can  be  seen  from  the  frequency  with  which 
objections  are  raised.  On  a  sliding scale,  the  concerned  Member  States 
may  be  rated.  With  such  a  grading,  Luxembourg  emerges  as  the  Member 
State  most  consistently  'tak:lng  Into  due  consideration'  the  first 
authorisation  I.e.  In  all  cases  the  first  authorisation  has  been 
accepted  (unless  the  Committee  opinion  has  subsequently  been 
negative).  At  the  other  extreme,  Italy  has  systematically  raised 
reasoned  object Ions  In  93%  of  appllcat Ions,  whilst  the  Nether lands 
have  raised  objections  In  92%  of  appl !cations  which  they  have 
received. 
Frequency  of 
systematic 
BE 
objections  88 
raised,  as  a  (%) 
DK 
83 
DE  GR  ES 
85  48  67 
FR  IR  IT  LX  NL  UK 
74  55  93  0  92  86 
3.3  On  the  Initiative  of  the  Chairman,  the  CPMP  adopted  a  programme 
for  Improving  the  efficiency  of  Its  procedures  In  March  1989.  As 
part  of  this programme,  a  number  of  Innovations  were  Introduced. 
a)  In  February  '88,  app I I cants  were  requested  mak:e  ava I I ab I e  theIr 
single written  response  to objections  raised  30  work:lng  days  before 
the  application would  be  considered  by  the  CPMP. 
b)  The  CPMP  Introduced  In April  '88  an  Informal  meeting  of  rapporteurs 
of  concerned  Member  States  which  considers  the  objections  raised 
and  the  responses  received,  before  the  formal  meeting of  the  CPMP. 
c)  Since  May  '89,  for  all  positive  opinions,  the  CPMP  attaches  a 
summary  of  product  characterIstIcs  {prepared  In  accordance  wIth 
Article  4a  of Directive 65/65/EEC). 
d)  In  November  '89  the  role  of  the  "rapporteur"  ( 111/3479/89)  In  the 
multi-state procedure  was  clarified. - 18  -
Arising  from  these  Improvements,  and  the  regular  exchanges  between  the 
Member  States,  the  resolution of objections has  been  facilitated. 
However,  the  fundamental  problem  still  remains,  which  Is  that 
objections  are  systematically  made  to  every  multi-state  application 
and  each  appl lcatlon  has  to  be  discussed  centrally  In  Brussels. 
Clearly  the  system  was  neither  designed  not  resourced  to  cope  with 
such  a  workload. 
3.4  The  CPMP  has  given  92  opinions  for  multi-state  applications  up  and 
Including  October  '90.  Of  these  83  have  been  positive  (on  a  simple 
majority  basis).  However  this  figure  can  only  be  taken  as  a  guide  as 
many  of  these  opinions  In  fact  contain  a  dissension  from  one  or  more 
Member  States. 
Of  the  92  opinions, 
*  61  have  been  unanimously  positive  (28  of  41  In  former  procedure), 
*  14  posIt I  ve  and  4  neg at I  ve  opInIons  have  had  a  sIng I  e  d 1  ssent 1  ng 
Member  State, 
*  3  posIt I  ve  and  3  negatIve  opInIons  have  had  two  dIssentIng  Member 
States, 
*  3  positive opinions  have  had  three dissenting Member  States, 
*  2  positive opinions  have  had  four  dissenting Member  States. 
3.5  In  cases  where  a  Member  State  dissents  from  the  opinion  of  the  CPMP, 
the  reasons  for  their  position are  given  In  the opinion,  as well  as  an 
Indication  of  what  corrective  action  may  be  taken  by  the  applicant. 
However,  as  the  multi-state  procedure  does  not  provide  for  an  appeal 
mechanism,  once  the opinion  Is  given,  any  further  Information  suppl led 
or  any  further  appeal  takes  place  nationally  and  In  accordance  with 
solely  national  provisions.  Nevertheless,  the  CPMP  follow  closely  the 
outcome  of  final  decisions  until  all  concerned  Member  States  have 
properly notified  the Committee. - 19  -
3.6  The  devolution  of  the  resolution  of  outstanding  problems  back  to 
national  procedures  has  caused significant  problems: 
Article  14.3  of  Directive  75/319/EEC  as  amended,  requires  notffatlon 
by  the  Member  States  to  the  Committee  of  decisions  on  action  arising 
from  opinions  of  the  CPMP.  Unfortunately,  delays  considerably  longer 
than  the  given  60  days  have  been  evidenced.  Some  of  the  delay  Is  of 
course  caused  by  the  fa I I  ure  of  the  app I I  cant  to  supp I y  the  mIssIng 
data  In  an  efficient  manner.  An  I I lustratlon  of  the  extent  of  delays 
can  be  seen  from  the  following: 
No.  of  months  No.  of 
since opinion  procedures 
46  1 
39 
38  1 
35  2 
31  2 
27  2 
21  3 
18  1 
16  3 
14 
12  3 
10  2 
9  5 
7  2 
6 
Total  no.  of 
countries 
concerned 
7 
8 
10 
10 
16 
15 
21 
10 
13 
6 
17 
14 
26 
12 
5 
Add It I  on a I I  Y,  the  resulting  decisions,  each 
No.  of  countries 
who  have  not  finalised 
a  decision 
1 
1 
3 
2 
2 
5 
4 
5 
4 
4 
10 
4 
3 
taken  In  Isolation  of  the 
other,  1  nevI tab 1  y  lead  to  different  results  and  different  authorlzat-
Ions  In  the  Member  States. - 20  -
It  Is  for  this  reason  that  the  CPMP  has  focussed  attention on  the need 
to elaborate  a  guideline on  the  content  of  the  summary  of  product  cha-
racteristics,  such  that  harmonlsed  Information  may  be  made  available 
throughout  the  Community.  Work  on  this guideline  Is  progressing  and  a 
draft  Is  anticipated early  In  1991. 
4.  Hearings 
4.1  As  part  of  the  Improvements  Introduced  by  the  multi-state  procedure, 
the  opportunity  for  applicants  to  make  written  and  oral  explanations 
was  establ lshed  (Article  14  of  Directive  83/570/EEC).  Thus  a  company 
may  present  for  an  ora I  hearIng  In  cases  where  one  or  more  Member 
States  have  raised  reasoned  objections  In  the  multi-state  procedure, 
or  In  cases  where  one  or  more  Member  States  have  granted  a  marketing 
authorization  whl leone or  more  Member  States  have  refused  It  and  the 
question  has  been  referred  to  the  CPMP. 
4.2  Of  course,  the  concertatlon procedure  also has  a  facl I lty  for  hearings 
with  applicant  companies.  In  fact,  Informal  discussions  with  expert 
working  parties also occur  for  concertatlon applications. 
4.3  Companies  may  also  be  Invited  to  present  for  an  oral  hearing  In 
pharmacovlgllance'  cases  (see Chapter  IV). - 21  -
4. 4  A  I  though  there  are  no  forma I  ru I  es  of  procedure  for  the  conduct  of 
hearings,  the  CPMP  recommends  the  following  guidance: 
-The  appl lcant  should  I lalse  with  the  Member  State/rapporteur 
regarding  the  need  for  a  hearing.  The  hearing  should  focus  on  those 
Issues which  have  not  been  resolved  In  previous written submissions. 
-Without  wishing  to  specify  a  formal  time  limit,  the  CPMP  considers 
that  hearings  lasting  more  than  half  an  hour  will  not  usually  be 
necessary,  as  a  hearing  Is  held  to  allow  clarification  of 
outstanding  Issues  by  questioning  from  the members  of  the  CPMP. 
-Any  documents  to  be  used  In  conjunction  with  a  hearing  should  be 
distributed  to  the  members  of  the  CPMP  30  working  days  before  the 
meeting.  New  studies/data  cannot  be  fully  taken  Into  account  during 
such  a  short  hearing,  and  therefore  such  data  should  be  made 
available  to  the  Member  States  at  least  30  working  days  before  the 
meeting.  Very  large  volumes  of  new  data  may  require  a  deferral  of 
discussion  In  order  to allow adequate  time  for  consideration. 
- It  would  normally  be  appropriate  for  between  one  and  four  persons  to 
appear  on  behalf of  the  company  concerned. 
4.5  The  facl I tty  for  hearings  has  been  In  place since  1986.  Since  then  the 
usage  has  been  as  follows: 
Multi-state  procedure  :  31 
Concertatlon  procedure  10 
Pharmacovlgllance:  3 - 22  -
4.6  It  Is  Important  to  appreciate  that  a  hearing  takes  place  In  an 
environment  that  Is  multl-1 lngual  and  that  simultaneous  technical 
Interpretation  during  the  hearing  Is  necessary.  Equally,  given  the 
very  heavy  workload  of  the Committee,  and  the  consequent  necessity  for 
short  hearings,  It  Is  not  possible  to  resolve  detailed  and  .extensive 
technical  points,  and  dlfflclencles  In  the  dossier  cannot  be  overcome 
through  oral  presentations.  Therefore  the  value of  the oral  presentat-
Ion  should  not  be  over-estimated. 
5.  Evaluation of  the multi-state procedure 
5.1  On  the  basis of  the experience  now  gained,  It  Is  possible  to draw  some 
conclusions on  the operation of  the multi-state procedure: 
-The procedure  Is  popular  and  attractive to  Industry,  as evidenced  by 
the  number  of  appl lcatlons  received. 
-The eventual  outcome  of  a  procedure  Is  generally  positive,  which  Is 
consistent  with  the  underlying  philosophy,  bearing  In  mind  that  one 
Member  State has  already authorized  the product. 
-The  procedure  achieves  results,  although  not  by  the  principle 
foreseen  In  the  Directive,  but  rather  through  the  systematic  use  of 
the  provision set  up  for  dealing  with  obJections,  and  not  by  virtue 
of  Its normal  principle  for  functioning  I .e.  mutual  recognition. 
-The principle of mutual  recognition  as  It  underlines  the multi-state 
procedure,  has  never  worked.  Many  reasons  have  been  put  forward  to 
explain  this  Including  national  sovereignty  and  the  need  to  apply  a 
safeguard  clause,  administrative  requirements  In  Individual  Member 
States  and  the  absence  of  a  clear  national  legal  basis  for  the 
devolution of  responsibility  to  the first  authorizing Member  state. - 23  -
-The multi-state procedure,  although currently operating effectively, 
cannot  continue  to  do  so  If  each  and  every  case  Is  referred  to  the 
CPMP  because  due  consideration  Is  not  taken of  the  first  authorisat-
Ion.  Given  the  volume  Increase  In  the use of  the  procedure,  the  CPMP 
Itself  has  Identified  necessary  goals  In  Its  "Proposals  for  the 
Improvement  of  the  current  functioning  of  the  CPMP"  (I I 1/3476/89): 
-A changed  attitude  to  the multi-state  procedure  In  order  to obtain 
a  consistent  Improvement  In  mutual  recognition; 
- Improvement  of  the  technical  role of  the  CPMP,  especially  Intended 
to  render  efficient  the  concertatlon  procedure 
- Introduction of  a  binding  European  decision 
5.2  The  Commission  has  taken  account  of  the  views  of  the  Committee  for 
Proprietary Medicinal  Products  In  the  preparation of  Its proposals  for 
the  future  system  of  registration  of  medicinal  products  (mentioned 
above),  particularly  In  relation  to  the  necessity  for  the  highest 
scientific  standard  needed  for  the  assessment  of  applications  for 
market lng  author I  sat Ions  and  also  the  need  for  a  binding  European 
decision. - 24  -
IV.  CONCERTATION  PROCEDURE 
1.  ·Principles of  the concertatlon  procedure 
1.1  The  legal  rules  governing  the  special  Community  procedure  are set  out 
In  councl 1 Directive 87/22/EEC.  The  obJective of  the special  procedure 
Is  to enable  Questions  relating to the QUality,  safety and  efficacy of 
medicinal  products  developed  by  means  of  new  biotechnology  processes 
and  other  high  technology  medicinal  products  to  be  resolved  at 
Community  level  within  the  CPMP  before  any  national  decision  Is 
reached  concerning  a  marketing authorization. 
1.2  The  concertat lon  procedure  Is  obligatory  for  all  medicinal  products 
developed  by  means  of  the  following  biotechnological  processes  (List A 
of  the Annex  of  Directive 87/22/EEC): 
- recombinant  DNA  technology 
-control led  expression  of  genes  coding  for  biologically  active 
proteins  In  prokaryots  and  eukaryots,lncludlng  transformed mammal  lan 
cells 
- hybrldoma  and  monoclonal  antibody  methods 
1.3  In  addition,  applicants  for  marketing  authorization  for  the  following 
groups  of  products  may  reQuest  that  the  appllcat lon  be  considered 
under  this procedure  (List  B of  the Annex  of  Directive 87/22/EEC): 
- medicinal  product  developed  by  other  biotechnological  processes 
which  constitute a  significant  Innovation; 
·- medIc Ina I  product  admInIstered  by  means  of  new  de 1 1  very  systems 
which  constitute a  significant  Innovation; 
- medIc Ina I  products  contaInIng  a  new  substance  or  an  ent 1  re  1  y  new 
Indication which  Is  of significant  therapeutic  Interest; - 25  -
- new  medicinal  products  based  on  radio-Isotopes  which  are  of 
significant  therapeutic  Interest; 
-medicinal  products  the  manufacture  of  which  employs  processes  which 
demonstrate  a  significant  technical  advance  such  as  2-dlmentlonal 
electro-phoresis under  micro-gravity. 
1.4  The  timetable  for  the  concertatlon  procedure  Is  based  on  the  require-
ment  of  Article  7  of  Directive  65/65/EEC.  Since  the  applications 
relate  to  complex  processes  which  are  deemed  to  be  exceptional,  the 
rapporteur,  In  establishing  the  period  for  review,  systematically 
extends  the  time  period of  120  days  to  Include  the  additional  90  days 
provided  for  In  exceptional  cases  by  the directive. 
For  variations  however,  the  rapporteur  Is  at  liberty  to  reduce  the 
per lod  of  review  to  less  than  120  days,  to  as  short  a  tIme  as  Is 
practical,  given  the  nature of  the  variation. 
1.5  Given  the  very  complex  nature  of  the  applications  received  In  the 
concertatlon  procedure,  an  expert  working  party,  called  the  Biotech-
nology/Pharmacy  working  party,  was  established  In  1986  to  assist  In 
the scientific evaluation of  appl lcatlons. 
This  working  party  (see  Chapter  I,  paragraph  5),  whose  chairman  Is 
Dr .  G.  Sch I I d,  has  gIven  techn I  ca I  advIce  to  the  CPMP  In  the  many 
concertatlon appl lcatlons which  the  CPMP  has  considered. 
2.  Operation of  the  concertatlon  procedure 
Since  this directive  came  Into effect  on  1st  July  '87,  there  have  been 
applications  In  respect  of  30  medicinal  products.  Of  these  24  are  for 
List  A medicinal  products,  whl  le  6  are  for  List  B medicinal  products. 
Of  the  30  applications,  the  number  of  Member  States  concerned  Is  337. 
In  fact  25  appl lcatlons  concern alI  Member  States except  one. - 26  -
3.  Choice  of  rappporteur 
3.1  Unlike  the  multi-state  procedure,  no  Member  State  makes  a  decision 
regarding  marketing  authorization  prior  to  the  commencement  of  a 
concertatlon  procedure.  Therefore  the  applicant  may  Invite  the  Member 
State of  Its choice  to act  as  rapporteur. 
3.2  The  task of  rapporteur  Is  better distributed  between  the  Member  States 
than  In  the  multi-state  procedure,  as  can  be  seen  from  the  following 
(the  1/2  refers  to  an  application where  the  UK  and  Fr  acted  as  Joint 
rapporteurs). 
BE  OK  DE  GR  ES  FR  IR  IT  LX  NL  PO  UK  Total 
country of origin  1  5  4  - 4  1/2 1  2  4  - 8  1/2  30 
Recipient  country  29  29  29  25  28  29  28  28  27  29  27  29  337 
3.3  The  national lty  of  the  applicants.  (by  reference  to  their  group 
headQuarters)  points up  the  degree  of  Innovation of  the  pharmaceutical 
Industry.  15  of  the  appl lcatlons were  from  pharmaceutical  companies  of 
the  Community  (De- 6;  Dk- 4;  UK- 3;  It- 1;  Nl- 1),  while  13 
applicants  were  from  the  United  States,  and  one  each  from  Sweden  and 
Swl tzar land. - 27  -
4.  Variations 
A medicinal  product  which  has  been  considered  under  the  concertatlon 
procedure,  also  avails  of  co-ordinated  review  of  variations  or  ex-
tensions  to  the medicinal  product.  In  July  '89,  the  CPMP  clarified  the 
position  with  regard  to  variations  and  extensions.  Variations  always 
concern all  Member  States which  have  authorised  the medicinal  product. 
Given  that  the  medicinal  products  considered  under  this  procedure  are 
Innovatory  by  their  nature,  It  Is  not  surprising  that  a  high  number  of 
varIatIons  and  extensions  are  applied  for  each  year.  On  the  current 
database  of  medicinal  products,  the  number  of  variations  has  been  16. 
Of  these  16  variations,  9  opinions  have  been  given,  alI  of  which  have 
been  positive. 
5.  Outcome  of  the  procedure 
5.1  Up  to  October  '90,  the  CPMP  has  given  11  opinions  under  the 
concertat ion  procedure.  One  opinion  was  given  pr lor  to  the  formal 
Implementation  of  the  Directive,  to  allow  a  'test-run'  of  the 
procedure. 
5.2  Of  the  11  opinions  given,  all  have  been  positive.  Whilst  this  may 
sound  Impressive,  In  fact,  the  practice  Is  for  applicants  to  withdraw 
an  appl lcatlon  when  It  becomes  evident  that  a  negative  opinion  would 
be  given.  This  practice  of  withdrawing  the  application  Is  entirely 
consistent  with  a  company's  responsibility  to  patients,  I.e.  If  a 
medIc Ina I  product  does  not  meet  the  necessary  standards  of  qua I I ty, 
safety  and  efficacy  Is  should  not  be  marketed.  A  total  of  two 
appl !cations  have  been  withdrawn  to date. - 28  -
5.3  For  the  11  opinions  given  for  first  applications,  these  represent  121 
national  applications,  for  which  79  authorisations  have  been  granted 
~nd 42  are  awaiting  national  decision.  If  the 9 opinions on  variations 
are  added  to  this,  the  total  number  of  national  applications  would 
rIse  to  217,  of  whIch  121  have  receIved  author I  sat Ions  and  96  are 
awaiting national  decision. 
A problem  similar  to  that  encountered  with  the  multi-state  procedure 
Is  also  evident  with  the  concertatlon  procedure.  This  Is  the  delay 
between  the giving of  an  opinion  by  the Committee  and  the notification 
of  a  national  decision  on  that  opinion.  By  far  the  worst  case  Is  the 
application,  for  which  two  Member  States  are  outstanding  for  four 
years on  a  decision on  the  CPMP  opinion.  An  I I lustratlon of  the extent 
of  delays  can  be  seen  from  the  following: 
No.  of months 
since opinion 
No.  of 
procedures 
Total  no.  of 
countries 
concerned 
No.  of  countries 
who  have  not  notified 
a  decision 
--------------------------------------------------------------------
27 
26 
24 
16 
12 
10 
7 
1 
1 
1 
2 
1 
1 
1 
12 
12 
1 
19 
11 
12 
12 
1 
1 
1 
4 
5 
6 
3 - 29  -
6.  Products  authorised as  a  result  of  the concertatlon  procedure 
In  accordance  with  Article  4.8.a)  of  Directive  65/65/EEC,  an  abridged 
appl lcatlon  for  a  medicinal  product  essentially similar  to a  medicinal 
product  of  List  A or  List  8,  can  be  made  after  a  period  of  ten  years 
from  the  date  of  first  authorisation  In  the  Community.  The  following 
products  have  been  consIdered  under  the  concertat I  on  procedure  and 
have  received  their  first  authorisation  In  the Community: 
1.  ORTHOCLONE  (OKT3);  authorization 
authorized  In  France  on  03.06.1986: 
holder  Is  Cllag;  first 
2.  NORDITROPIN 
holder  Is 
28.04.1988: 
(recombinant  Human 
Nordlsk  Gentofte; 
growth  hormone);  authorization 
first  authorized  In  Denmark  on 
3.  INSULIN  (recombinant  lnsul In);  authorization  holder  Is  Novo 
lndustrl  A/S;  first  authorized  In  Italy on  06.07.1988: 
4.  EPREX  (erythropoeltln);  authorization  holder  Is  Cllag;  first 
authorized  In  France  on  04.08.1988: 
5.  MONOCLATE  P  (Mab  purified  factor  VIII);  authorization  holder  Is 
Armour  Pharmaceutical  Company;  first  authorized  In  Italy  on 
03.10.1989: 
6.  PROLEUKIN  (recombinant  lnterleukln);  authorization  holder  Is 
Eurocetus;  first  authorization  In  Spain on  23.06.1989: 
7.  MYOSCINT  (antlmyosln  Fab  DTPA);  authorization  holder  Is 
Centocor  Europe;  first  authorization  In  Italy on  13.06.1989: a. 
- 30  -
ENGERIX  - B  (recombinant  hepatitis  B 
holder  Is  Smith  Kline  French  Labo; 
Belgium  on  10.12.1986·: 
vaccine);  authorization 
first  authorization  In 
9.  RECORMON  (erythropoeltln);  authorization  holder  Is  Boehringer/ 
Mannhelm;  first authorized  In  Denmark  on  01.03.1990: 
10.  GENOTROPIN  (recombinant  human  growth  hormone);  authorization 
holder  Is  Kabl  Blopharma;  first  authorization  for  16  I.U.  In 
Denmark  on  19.02.1990: 
11.  RETROVIR  (zldoduvlne);  authorization  holder  Is  The  Wellcome 
Foundation;  first  authorisation  for  asymptomatic  patients  In 
Denmark  on  20.06.1990. - 31  -
V.  PHARMACOVIGILANCE 
1.  Continued  safety monitoring 
1.1  During  the  period  of  marketing  a  medicinal  product,  It  may  be 
necessary,  In  order  to  safeguard  publ lc  health,  to  take  urgent 
measures  such  as  the  modification  of  the  terms  of  marketing 
authorization,  or  Its  even  suspension.  The  general  activity  of 
monitoring  the  side-effects  of  a  medicinal  product,  Including  any 
active  Investigation  of  such  Incidence,  may  be  Included  within  the 
meaning  of  pharmacovlgllance. 
1.2  Ever  since  Its  establ lshment,  the  CPMP  has  exchanged  Important 
Information  (In  accordance  with  Directive 75/319/EEC  Articles 30  & 33) 
on  matters  of  pharmacovlgllance.  Internal  procedures  had  been 
described  In  1979  (111/1816/79)  and  1982  (111/1917/82)  Including  a 
list of  contact  people  for  a  system of  rapid alert. 
1.3  Given  the  Importance  of  this  activity  and  the  need  for  a  most 
effective  exchange  of  Information,  particularly  when  publ lc  health  Is 
at  r lsk,  the  CPMP  has  recently  developed  further  the  procedures  In 
this area. - 32  -
2.  Drug  monltorlng/pharmacovlgllance: 
2.1  In  the Member  States,  different  systems of  pharmacovlgllance  apply  and 
consequently,  Information  on  medicinal  products  Is  collected  In 
different  ways.  However,  regardless  of  the  method  of  collection used, 
be  It  spontaneous  ADR  reports,  results of  new  studies,  etc.,  the  CPMP 
considered  It  essential  that  such  Information,  properly  validated,  be 
communicated  as  soon  as  possible  to  the  competent  authorities of  the 
other  Member  States.  Therefore  a  system  of  communication  falling  Into 
two  parts,  I .e.  rapid  alert  and  regular  notification,  was 
estab I I  shed. 
2.2  In  the  Rapid  Alert  mechanism,  the  competent  authority  of  the  Member 
State  of  origin,  I.e.  the  source  of  the  Information,  Is  responsible 
for  sending  out  the  Information  to  all  other  Member  States  and  the 
Commission  directly,  with  a  copy  to  the  CPMP  secretariat. 
On  the basis of  experience with alert  reports,  an  INFO  FAX  was  adopted 
whIch  a I I  ows: 
*  the  INN  name  < as  the main  Identification);  brand  names,  and  company 
names  although  not  necessarily  the  same  In  all  Member  States,  are 
also be  stated. 
*the fax  Includes  sufficient  details of  the  Incident/report  to  allow 
al 1  recipients  to appreciate  the  significance of  the  report. 
*following  a  rapid  alert  communication,  the  competent  authority  of 
the  Member  State  of  origin  prepares  a  background  note  for  the  next 
CPMP  meeting. - 33-
2.3  With  Regular  Communication,  the  exchange  of  pharmacovlgllance  data 
takes  place  In  the  CPMP.  Such  exchange  Is  a  fundamental  responslbl I lty 
of  the  Committee.  However,  given  Its  workload,  the  time  of  the 
Committee  can  be  maximized  by  a  prel lmlnary  screening of  routine data. 
Equally  Important  Is  the  communication  of  data on  defective batches of 
medicinal  products,  which  may,  In  some  cases,  be  of  Interest  to  the 
pharmacovlgllance  activity.  The  working  party  of  the  Pharmaceutical 
Inspectors  have  establ lshed  a  system  for  notification and  rapid action 
In  these  circumstances. 
3.  Screening of  Information 
3.1  The  growing  Importance  of  pharmacovlgl lance  problems  discussed  by  the 
CPMP,  Identified  the  need  for  a  special lzed  group of experts dedicated 
to  pharmacovlgllance.  with  a  view  to  screening  the  large  volume  of 
Information  and  providing  technical  preparation  for  the  CPMP  meeting, 
leading  to  the  setting  up  of  a  pharmacovlgllance  working  party  as 
mentioned  In  Chapter  I,  paragraph  5. 
This  group  was  set  up  In  February  1989,  and  a  first  report  on 
pharmacovlgllance  In  the  Member  States  was  Issued  In  September  1989 
(report  on  pharmacovlgllance  I I 1/3577/89). 
3.2  The  CPMP  continues  Its  responsibility  for  pharmacovlgllance  with  on-
going  procedures: 
*A  DRUG  INFORMATION  monitor  which  Identifies  selected  products  and 
updates  the  Information  on  marketing  authorization  status  and 
related changes; 
*  Pharmacovlgllance  HEARINGS  with  companies,  eventually  leading  to 
pharmacovlgllance opinions; - 34  -
*The  standardization  of  the  SUMMARY  OF  PRODUCT  CHARACTERISTICS  for 
some  products  of  Community  Interest  for  which  adverse  effects  have 
been  Identified which  require changes  to the  product  particulars. 
4.  Outcome  of  pharmacovlgllance activity 
4.1  In  total,  the  CPMP  has  given  8  opinions on  medicinal  products  arising 
from  pharmacovlgl lance  reports,  covering  the  following  substances: 
Aspirin 
Lofepramlne 
Suprofen 
lsotretlnoln 
lsoxlcam 
Flunarlzlne 
Flecanlde/Encalnlde 
Glafenlne/Fioctafenlne 
4.2  A total  of  8  rapid  alerts  have  been  exchanged  In  the  last  two  years, 
using  the  INFO  FAX  mechanism. 
4.3  The  Committee  has  considered  the  following  products  In  Its  programme 
of monitoring  from  1988  to  1990: 
Adrlanomyclne,  Arteparon,  Atlvan,  Budesonlde,  Carbosylan,  Cronasslal, 
Dlprlvan,  Exlfone,  Fenfluramlne,  Fenoterol,  Flecanlde,  Flunarlzlne, 
Fluoxetlne,  Glafenlne/floctafenlne,  Lidocaine,  Propacetamol,  PPSB, 
Prazosln,  Phenothiazine,  Ibuprofen,  lsotretlnoln,  lsoxlcam, 
Methaqualone,  Metlpranolol,  Mlanserln,  Nltrendlplne,  Nitrofurazone/ 
Nitrofurantoin,  Noscaplne,  Retinol,  Segontln,  Slmvastatlne,  Sodium 
Aurothlomalate,  Sulphamethoxazole,  Sulphltes,  Terconazole, 
Thai ldomlde,  Tlclopldlne,  Trlmethoprlm,  Tryptophan,  Warfarin. - 35  -
VI.  INTERNATIONAL  TRADE  AND  OTHER  ACTIVITIES 
1.  International  Harmonisation 
1.1  With  the  adoption  and  Implementation  of  Community  standards  and  texts 
In  the  pharmaceutical  field,  the  acceptance  of  these  standards  and 
formats  Internationally  has  grown.  The  Notice  to  Appl !cants  format  for 
the  preparation  of  the  dossier  Is  also  accepted  In  the  Nordic 
countries  and  by  EFTA.  The  guideline  on  Good  Manufacturing  Practice 
has  been  accepted  by  the  World  Health  Organisation.  The  guideline  on 
stability  testing  Is  the  first  of  Its  kind  and  caters  for  multiple 
cl lmatlc  zones.  EQually  when  embarking  on  more  detal led  activity,  the 
CPMP  first  looks  to  Internationally  recognised  methods  and  In  general 
would  adopt  these  If  appropriate.  For  example,  the  WHO  drug monitoring 
system. 
1.2  During  1989  therefore,  both  the  Nordic  Councl I  and  EFTA  were  Invited 
to  liaise  with  the  technical  working  parties  of  the  CPMP.  In  turn, 
Community  experts  are  Invited  to  technical  meetings  of  the  Nordic 
Councl I  and  EFTA.  Such  exchange  of  technical  expertise  allows  for  the 
approximation  of  standards  and  the  removal  of  technical  barriers  to 
trade. 
1.3  The  convention  relating  to  the  elaboration of  a  European  Pharmacopoeia 
was  signed  In  1964  within  the  framework  of  the  Councl I  of  Europe.  The 
European  CommunIty  gave  I  egIs I  at I  ve  force  to  the  standards  of  the 
European  Pharmacopoeia  In  Directive 75/318/EEC  and  In  November  1989,  a 
protocol  for  the  accession  of  the  EEC  to  the  European  Pharmacopoeia 
was  opened  for  signature  by  participating  States.  The  Protocol  will 
enter  Into  force  after  Its  ratification  by  all  19  states  which  are 
Parties  to  the  Convention. - 36  -
1.4  In  keeping with  the general  approximation  of scientific standards,  the 
Commission  has  established  liaison  with  the  United  States  Food  and 
Drug  Administration  (FDA).  Biannual  meetings  take  place  where 
exchanges  of  Information  facilitate  understanding.  The  expertise  of 
the  CPMP  has  been  fundamental  In  the  preparation  and  successful 
outcome  of  these meetings. 
1.5  Following  various  missions  by  European  experts  and  the  Commission  and 
In  particular!  the  successful  mission  to  Japan  In  September  1988, 
regular  I lalson  with  representatives  of  the  Japanese  Ministry  of 
Health  and  Welfare  (Koselcho)  Is  maintained.  The  appointment  of  a 
pharmaceutical  expert  to  the  Japanese  delegation  to  the  European 
Community  In  Brusse Is  has  great I  y  assIsted  the  exchange  of 
Information. 
2.  International  Conference  on  Harmonisation 
2.1  Arising  from  the  excellent  relations  which  have  developed,  the 
Commission  In  association with  the  FDA  and  Koselcho  authorities,  have 
agreed  to  Jointly  sponsor,  with  the  International  pharmaceutical 
Industry  (IFPMA;  EFPIA;  US-PMA;  JPMA),  an  International  conference  on 
the  harmonisation  of  technical  reQuirements  for  registration  of 
pharmaceuticals  for  human  use,  to  be  held  In  Brussels  In  November 
1991. - 37  -
2.2  This conference  has  as objectives: 
- to  provide  a  unique  forum  for  dialogue  between  the  main  regulatory 
authorities and  the  pharmaceutical  companies  worldwide; 
-to  Identify  the  degree  of  pharmaceutical  harmonisation  already 
achieved  bl laterally and  the outstanding differences; 
-to  agree  on  an  action  programme  to  complete  International 
harmonisation  (1991  - 1996)  with  a  view  to  prevent  unnecessary 
repetition of  human  and  animal  testing  and  to  reduce  pharmaceutical 
research  and  development  costs. 
3.  Intra-Community  Trade 
3.1  From  the  previous  reports  (cited  above)  and  from  the  many  economic 
analyses  (e.g.  The  Cost  of  Non-Europe  In  the  Pharmaceutical  Industry, 
Volume  15;  catalogue  number  CB  -PP  -88 -P14  -EN  -c.  aval lable  from  the 
Office  for  Official  Publ lcatlons  of  the  European  Communities), 
approximately  67%  of sales of medicinal  products  In  the  Community  come 
from  the  Member  States.  This  level  has  been  relatively  constant  for 
the  last  decade. 
3.2  Figures  for  the  geographic  distribution  of  exports  (for  bulk  and 
finished  pharmaceuticals)  are  given  In  Annex  4,  as  well  as  the  trade 
balance  for  pharmaceuticals  for  each  of  the  Member  States. - 38  -
3.3  Even  though  the  nUmbers  of multi-state and  concertatlon procedures are 
growing,  they  only  represent  less  than  10%  of  the  total  number  of 
applications  made  In  the  Community  each  year.  Therefore  the  Impact  of 
the  procedures  on  Intra-Community  trade  has  not  been  possible  to 
quantify,  but  may  be  assumed  not  to be  substantial.  However,  what  has 
been  significant  has  been  the  progress  of  harmonisation  which  already 
has  produced  savings  and  reduced  costs,  e.g.  a  single  format· for 
app I I  catIons,  non-repetItIon  of  testIng.  the  same  requIrements 
throughout  the  Community.  It  may  equally  be  said  that  the  procedures 
have  fac I II tated  Intra-CommunIty  trade  and  encouraged  an  apprec I  at. I  on 
of  the  resulting  commercial  opportunities,  leading  to  an  attitude  of 
Community  aval lab I I lty of medicinal  products. Annex  1 
Annex  2 
Annex  3 
Annex  4 
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Geographical  distribution of  exports of 
finished  pharmaceuticals Annex  1 
LIST  OF  MAJOR  COMMUNITY  TEXTS  APPLYING  TO  MEDICINAL  PRODUCTS 
-COUNCIL  DIRECTIVE  65/65/EEC  of  26  January  1965  on  the  approximation of 
provisions  laid  down  by  law.  regulation or  administrative action  relating 
to proprietary medicinal  products  (O.J.  n°  22  of 9.2.65) 
-COUNCIL  DIRECTIVE  75/318/EEC  of  20  May  1975  on  the  approximation of  the 
laws  of  Member  States relating  to analytical.  pharmacotoxlcologlcal  and 
clinical  standards and  protocols  In  respect  of  the  testing of  proprietary 
medicinal  products  (O.J.  n°  L 147  of  9.6.75) 
-COUNCIL  DIRECTIVE  75/319/EEC  of  20  May  1975  on  the  approximation of 
provisions  laid  down  by  law.  regulation or  administrative action  relating 
to proprietary medlclnaJ  products 
-COUNCIL  DECISION  75/320/EEC  of  20  May  1975  setting up  a  Pharmaceutical 
Committee  (O.J.  n°  L 147  of  9.6.75) 
-COUNCIL  DIRECTIVE  78/25/EEC  of  12  December  1977  on  the  approximation of 
the  laws  of  the Member  States relating  to  the  colouring matters which  may 
be  added  to medicinal  products  (O.J.  n°  L 11  of  14.1.78) 
-COUNCIL  DIRECTIVE  81/851/EEC  of  28  September  1981  on  the  approximation of 
the  laws  of  the  Member  States relating  to veterinary medicinal  products 
(O.J.  no  L 317  of 6.11.81) 
-COUNCIL  DIRECTIVE  81/852/EEC  of  28  September  1981  on  the  approximation of 
the  laws  of  the Member  States relating  to analytical.  pharmaco-toxlco-
loglcal  and  clinical  standards  and  protocols  In  respect  of  the  testing. of 
veterinary medicinal  products  (O.J.  n°  L 317  of 6.11.81) 
-COMMISSION  COMMUNICATION  on  paral lei  Imports  of  proprietary medicinal 
products  for  which  marketing  authorizations have  already been  granted 
(O.J.  n°  C 115  of 6.5.82) 
- COUNCIL  DIRECTIVE  83/189/EEC  of  28  March  1983  laying  down  a  procedure  for 
the  provision of  Information  In  the  field of  technical  standards and 
regulations  (O.J.  n°  L 109  of  26.4.83) 
-COUNCIL  DIRECTIVE  83/570/EEC  of  26  October  1983  amending  Directives 
65/65/EEC.  75/318/EEC  and  75/319/EEC  on  the  approximation of  provisions 
laid  down  by  law.  regulation or  administrative action  relating  to 
proprietary medicinal  products  (O.J.  n°  L 332  of  28.11.83) 
- COUNCIL  RECOMMENDATION  83/571/EEC of  26  october  1983  concerning  tests 
relating to  the  placing on  the  market  of  proprietary medicinal  products 
(O.J.  no  L 332  of  28.11.83) 
-COMMISSION  COMMUNICATION  on  the  compatlbl I lty with Article  30  of  the  EEC 
Treaty of  measures  taken  by  Member  States relating  to price controls and 
reimbursement  of  medicinal  products  (O.J.  no  C 310  of  4.12.86) -2-
-COUNCIL  DIRECTIVE  86/609/EEC  of  24  November  1986  on  the  approximation of 
laws,  regulations  and  administrative  provisions of  the  Member  States 
regarding  the  protection of  animals  used  for  experimental  and  other 
scientific purposes  (O.J.  n°  L  358  of  18.12.86) 
-COUNCIL  DIRECTIVE  87/18/EEC of  18  December  1986  on  the  harmonization of 
laws,  regulations or  administrative  provisions  relating  to  the 
appl lcatlon of  the  principles of  good  laboratory  practice and  the 
verification of  their  applications  for  tests on  chemical  substances  (O.J. 
no  L  15  of  17.1.87) 
-COUNCIL  DIRECTIVE  87/19/EEC of  22  December  1986  amending  Directive 
75/318/EEC  on  the  approximation of  the  laws  of  the  Member  States  relating 
to analytical,  pharmaco-toxlcologlcal  and  cl lnlcal  standards  and 
protocols  In  respect  of  the  testing of  proprietary medicinal  products 
(O.J.  no  L  15  of  17.1.87) 
-COUNCIL  DIRECTIVE  87/20/EEC  of  22  December  1986  amending  Directive 
81/852/EEC  on  the approximation of  the  laws  of  the  Member  States relating 
to analytical,  pharmaco-toxlcologlcal  and  cl lnlcal  standards  and 
protocols  In  respect  of  the  testing of  veterinary medicinal  products 
(O.J.  n°  L  15  of  17.1.87) 
-COUNCIL  DIRECTIVE  87/21/EEC of  22  December  1986  amending  Directive 
65/65/EEC  on  the  approximation of  provisions  laid  down  by  law,  regulation 
or  administrative action  relating  to  proprietary medicinal  products  (O.J. 
n°  L  15  of  17.1.87) 
-COUNCIL  DIRECTIVE  87/22/EEC  of  22  December  1986  on  the  approximation of 
national  measures  relating  to  the  placing on  the  market  of  high 
technology  medicinal  products,  particularly  those  derived  from 
biotechnology  (O.J.  no  L 15  of  17.1.87) 
- COUNCIL  RECOMMENDATION  87/176/EEC of  9  February  1987  concerning  tests 
relating  to  the  placing on  the  market  of  proprietary medicinal  products 
(O.J.  n°  L 73  of  16.3.87) 
-COUNCIL  DIRECTIVE  88/182/EEC  of  22  March  1988  amending  Directive 
83/189/EEC  laying  down  a  procedure  for  the  provision of  Information  In 
the  field of  technical  standards and  regulations  (O.J.  no  L 81  of 
26.3.88) 
-COUNCIL  DIRECTIVE  88/320/EEC of  9  June  1988  on  the  Inspection  and 
verification of  Good  Laboratory  Practice  (GLP)  (O.J.  no  L  145  of  11.6.88) 
-COUNCIL  DIRECTIVE  89/105/EEC  of  21  December  1988  relating  to  the 
transparency of  measures  regulating  the  pricing of  medicinal  products  for 
human  use  and  their  Inclusion within  the  scope of  national  health 
Insurance  systems  (O.J.  n°  L 40  of  11.2.89) 
-COUNCIL  DIRECTIVE  89/341/EEC  of  3  May  1989  amending  Directives 65/65/EEC, 
75/318/EEC  and  75/319/EEC  on  the  approximation of  provisions  laid down  by 
law,  regulation or  administrative  action  relating  to proprietary 
medicinal  products - 3  -
- COUNCIL  DIRECTIVE  89/342/EEC  of  3  May  1989  extending  the  scope of 
Directives 65/65/EEC  and  75/319/EEC  and  laying  down  additional  provisions 
for  Immunological  medicinal  products  consisting of  vaccines,  toxins or 
serums  and  allergens  · 
- COUNCIL  DIRECTIVE  89/343/EEC  of  3  May  1989  extending  the  scope of 
Directives 65/65/EEC  and  75/319/EEC  and  laying  down  additional  provisions 
for  radlopharmaceutlcals 
- COUNCIL  DIRECTIVE  89/381/EEC  of  14  June  1989  extending  the  scope of 
Directives 65/65/EEC  and  75/319/EEC  on  the  approximation of  provisions 
laid  down  by  law,  regulations or  administrative action  relating  to 
proprietary medicinal  products  and  laying  down  special  provisions  for 
medicinal  products  derived  from  human  blood or  human  plasma 
- COUNCIL  DIRECTIVE  90/18/EEC  of  18  December  1989  adapting  to technical 
progress  the  Annex  to Councl I  Directive 88/320/EEC  on  the  Inspection  and 
verification of  Good  Laboratory Practice  (GLP) 
-COUNCIL  REGULATION  (EEC)2377/90  of  26  June  1990  laying  down  a  Community 
procedure  for  the establishment  of  maximum  residue  limits of  veterinary 
medicinal  products  In  foodstuffs of  animal  origin 
-COUNCIL  DIRECTIVE  ...  / ...  /EEC  of  13  December  1990  amending  Directive 
81/851/EEC  on  the  approximation of  the  laws  of  the Member  States relating 
to veterinary medicinal  products 
'  -COUNCIL  DIRECTIVE  ...  / ...  /EEC  of  13  December  1990  extending  the  scope of 
Directive 81/851/EEC  on  the  approximation of  the  laws  of  the Member 
States relating  to veterinary medicinal  products  and  laying  down 
additional  provisions  for  Immunological  veterinary medicinal  products - 1  -
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I.  GUIDELINES  ADOPTED  BY  THE  CPMP  UP  TO  DECEUBER  1988: 
PUBLISHED  IN  VOLUME  Ill  OF  THE  SERIES  •RULES  GOVERNING  MEDICINAL  PRODUCTS  IN  THE  EUROPEAN 
COMMUNITY"  (CATALOGUE  NUMBER:  CB-55-89-843-EN-c) 
2.  GUIDELINES  ADOPTED  FROM  DECEMBER  1988 TO  JULY  1990: 
PUBLISHED  (ADDENDUM  VOLUME  Ill,  CATALOGUE  NUMBER:  CB-59-90-936-EN-c) 
3.  GUIDELINES  ADOPTED  BY  THE  CPMP 
TITLE  NUMBER  LANGUAGE  DATE  OF  ADOPTION 
Local  tolerance  testing of medicinal  111/3979/89  EN-FR-DE  December  1990 
Radlopharmaceutlcals  111/3936/89  EN-FR  December  1990 
4.  GUIDELINES  RELEASED  BY  THE  CPMP  FOR  CONSULTATION 
TITLE  NUMBER  DATE  OF  DEADLINE  FOR  FINALIZATION 
LANGUAGE  RELEASE  COMMENTS 
Radlopharmaceutlcals  based  on  II 1/3487/89  Feb.  1990  01.09.1990  Ad  Hoc  Group 
monoclonal  antibodies of  human  Draft  no  5  March  1991 
origin  EN  CPMP  May  1991 
Val  ldatlon of  virus  removal  and 
Inactivation procedures 
111/8115/89  March  1990  01.10.1990  Biotech  Jan.  91 
Draft  no  6  CPMP  Feb.  91 
EN-FR 
Recommendations  for  the  development  I 11/58/89  July  90  15.01.1991  CPMP  May  1991 
of  non  cl lnlcal  testing strategies  Draft  no  7 
EN 
Categorisation of  medicinal  products  111/3862/89  July  90  15.01.1990  CPMP  May  1991 
for  use  In  pregnancy  Draft  no  5 
EN 
Investigation of  bloaval labl I lty  and  I I 1/54/89  July  90  15.01.1990  CPMP  March  1991 
bloeQulvalence  Draft  no  8 
EN 
Specifications and  control  tests on  111/3324/89  Dec.  90  01.06.1991  DIsc.  In  W. P. 
July  1991  the  finished  product  Draft  no  7 
Ethylene oxide 
EN-FR 
111/9261/90  Dec.  90 
Draft  no  1 
EN 
Cl  lnlcal  Investigation of  hypnotic  II 1/3855/89  Dec.  90 
medicinal  products  Draft  n°  3 
w 
31.03.1991  DIsc.  In  W. P. 
Apr I I  1991 
01.06.1991  Disc.  In  W.P. 
July  1991 GEOGRAPHICAL 
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GEOGRAPHICAL  DISTRIBUTION  OF  EXPORTS  1988. 
EXPORTS  1988  BULK  PHARMACEUTICALS. 
(mecus)  (Vitamins,Hormones,Vegetable  Alkaloids,Antibiotics) 
TOTAL  INTRA  EXTRA  CLASS  1  EFTA  USA  JAPAN  CLASS2  EAST.EUR 
FR  GERMANY  739  38%  62%  35%  8%  17%  3%  20%  3% 
FRANCE  325  46%  sn  34%  21%  n  S%  18%  1% 
ITALY  513  33%  67%  44%  15%  1 S%  10%  l6%  a 
BELG.-LUXBG  89  85%  IS%  8%  4%  1%  1%  6%  0% 
UTO.  KINGDO  376  42'X.  58%  3  9%  6%  13%  13%  17%  1 ,. 
IRELAND  118  71%  29'X.  25%  9%  3%  11%  3%  1% 
DENMARK  118  48%  52%  37%  11%  11%  0%  11%  .n 
GREECE  8  31%  69%  23'1.  8%  7%  7%  41%  2% 
SPAIN  182  23'1.  77%  32%  13%  6%  9%  32%  4% 
PORTUGAL  145  sa  43%  2.2%  3%  12'X.  3%  18%  3% 
NETHERLANDS  66  95%  S%  -~' 
0%  1%  0%  2%  1% 
EUR  12  2,680  44%  56%  34%  11%  12%  6%  17%  2% 
EXPORTS  1988  FINISHED  PHARMACEUTICALS 
(mecus)  (CN  30) 
TOTAL  INTRA  EXTRA  CLASS  1  EFTA  USA  JAPAN  CLASS2  EAST.EUR 
FR  GERMANY  3,040  39%  61%  45%  20%  3%  16%  13%  2% 
FRANCE  l '8  6 s  42%  58%  12%  6%  2%  2%  4 S%  1% 
ITALY  58 s  52%  48%  19%  6%  8%  1%  26%  2% 
BELG.-LUXBG  914  58%  42%  21%  13%  1%  2%  19%  2% 
UTD.  KINGDO  2. 1 56  41 '%  59%  31 '%  9%  9%  4%  27%  1% 
IRELAND  3 54  64%  36%  30%  4%  16%  4%  7Y.  0% 
DENMARK  596  39Y.  61Y.  45%  25%  8%  9Y.  14%  2Y. 
GREECE  46  58%  42Y.  sex.  Of.  Of.  Of.  3SY.  0% 
SPAIN  362  47Y.  53%  6%  4%  0%  0%  45%  0% 
PORTUGAL  31  30%  70Y.  14%  9%  4%  Of.  56%  Of. 
NETHERLANDS  777  51%  49Y.  31%  18%  a  3%  16%  1% 
EUR  12  10,725  44%  56%  30%  13%  5%  7%  24%  a 
Source:Eurostat. TRADE  IN  PHARMACEUTICALS  1988. 
FINISHED  BULK 
PHARMACEUTICALS  PHARMACEUTICALS 
(mecus) 
IMPORTS  EXPORTS  BALANCE  IMPORTS 
GERMANY  1 '623  3,040  1 '4 1 6  482 
FRANCE  684  1 '86 5  1 ' 181  667 
ITALY  1,058  58 5  -473  613 
BELG.-LUXBG  734  920  l 8 6  l 4 l 
UTD.  KINGDO  l '0  9 4  2' 1 56  1 '0 61  ·220 
IRELAND  213  3 54  1 4 1  55 
DENMARK  280  59 6  316  86 
GREECE  128  47  -81  4 5 
SPAIN  29 5  362  67  233 
PORTUGAL  126  31  -96  49 
NETHERLANDS  763  786  23  130 
EUR  l 2  6,998  10,741  3,743  ?  -n, 
Source:Eurostat. 
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